Similar articles for PMID: 26227101

Year	Number of Results
2012	4
2013	12
2014	20
2015	23
2016	22
2017	12
2018	14
2019	8
2020	15
2021	17
2022	13
2023	7
2024	0

1

Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers.

Brealey N, Gupta A, Renaux J, Mehta R, Allen A, Henderson A. Brealey N, et al. Int J Clin Pharmacol Ther. 2015 Sep;53(9):753-64. doi: 10.5414/CP202390. Int J Clin Pharmacol Ther. 2015. PMID: 26227101 Free PMC article. Clinical Trial.

2

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.

Day NC, Kumar S, Criner G, Dransfield M, Halpin DMG, Han MK, Jones CE, Kaisermann MC, Kilbride S, Lange P, Lomas DA, Martin N, Martinez FJ, Singh D, Wise R, Lipson DA. Day NC, et al. Respir Res. 2020 Jun 5;21(1):139. doi: 10.1186/s12931-020-01398-w. Respir Res. 2020. PMID: 32503599 Free PMC article. Clinical Trial.

3

Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.

Mehta R, Farrell C, Hayes S, Birk R, Okour M, Lipson DA. Mehta R, et al. Clin Pharmacokinet. 2020 Jan;59(1):67-79. doi: 10.1007/s40262-019-00794-w. Clin Pharmacokinet. 2020. PMID: 31321713 Free PMC article. Clinical Trial.

4

Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.

Bremner PR, Birk R, Brealey N, Ismaila AS, Zhu CQ, Lipson DA. Bremner PR, et al. Respir Res. 2018 Jan 25;19(1):19. doi: 10.1186/s12931-018-0724-0. Respir Res. 2018. PMID: 29370819 Free PMC article. Clinical Trial.

5

Pharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trial.

Hu C, Jia J, Dong K, Luo L, Wu K, Mehta R, Peng J, Ren Y, Gross A, Yu H. Hu C, et al. PLoS One. 2015 Mar 27;10(3):e0121264. doi: 10.1371/journal.pone.0121264. eCollection 2015. PLoS One. 2015. PMID: 25816315 Free PMC article. Clinical Trial.

6

The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.

Kato M, Tomii K, Hashimoto K, Nezu Y, Ishii T, Jones CE, Kilbride S, Gross AS, Clifton CS, Lipson DA. Kato M, et al. Int J Chron Obstruct Pulmon Dis. 2019 Dec 6;14:2849-2861. doi: 10.2147/COPD.S226601. eCollection 2019. Int J Chron Obstruct Pulmon Dis. 2019. PMID: 31839705 Free PMC article. Clinical Trial.

7

Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.

Lee LA, Bailes Z, Barnes N, Boulet LP, Edwards D, Fowler A, Hanania NA, Kerstjens HAM, Kerwin E, Nathan R, Oppenheimer J, Papi A, Pascoe S, Brusselle G, Peachey G, Sule N, Tabberer M, Pavord ID. Lee LA, et al. Lancet Respir Med. 2021 Jan;9(1):69-84. doi: 10.1016/S2213-2600(20)30389-1. Epub 2020 Sep 9. Lancet Respir Med. 2021. PMID: 32918892 Clinical Trial.

8

The pharmacodynamics, pharmacokinetics, safety and tolerability of inhaled fluticasone furoate and vilanterol administered alone or simultaneously as fluticasone furoate/vilanterol.

Kempsford R, Allen A, Bareille P, Hamilton M, Cheesbrough A. Kempsford R, et al. Clin Pharmacol Drug Dev. 2015 Jan;4(1):2-11. doi: 10.1002/cpdd.160. Epub 2014 Dec 5. Clin Pharmacol Drug Dev. 2015. PMID: 27127998 Clinical Trial.

9

Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults.

Li Y, Li H, Sheng Y, Du X, Yao Y, Luo X, Ma P. Li Y, et al. Clin Pharmacol Drug Dev. 2019 Aug;8(6):721-733. doi: 10.1002/cpdd.626. Epub 2018 Nov 14. Clin Pharmacol Drug Dev. 2019. PMID: 30427594 Clinical Trial.

10

A randomized, crossover study to investigate the pharmacokinetics and safety of inhaled fluticasone furoate and umeclidinium, administered separately and in combination via dry powder inhaler in healthy adult volunteers.

Yang S, Lee L, Mallett S, Ayer J, Wolstenholme A, Pascoe S. Yang S, et al. Adv Ther. 2015 Feb;32(2):157-71. doi: 10.1007/s12325-015-0184-6. Epub 2015 Feb 21. Adv Ther. 2015. PMID: 25700806 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

145 results

Results by year